Human Intestinal Microbiota in Obesity and Nutritional Transition (Micro-Obes)
|Study Design:||Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Primary Purpose: Health Services Research
|Official Title:||Human Intestinal Microbiota in Obesity and Nutritional Transition|
- weight loss [ Designated as safety issue: No ]
- intestinal microbiota genes [ Designated as safety issue: No ]identify new intestinal microbiota at basal levels and follow their evolution during the dietary program by using a sequence based method (SOLiD™ System: a massively sequencing platform).
- Body fat massusing dual-energy X-ray absorptiometry performed with a total body scanner (Hologic QDR 2500 densitometer)
- Food intakeusing 7 day dietary records at each time point
- plasma glucose
- adipose tissue genes [ Designated as safety issue: No ]Microarray
|Study Start Date:||September 2008|
|Study Completion Date:||March 2011|
|Primary Completion Date:||September 2009 (Final data collection date for primary outcome measure)|
Other: Caloric transition
French overweight (BMI > 27) and obese people (BMI > 30 kg/m2, N=50) will be submitted to a low calorie diet (1200 Kcal) for 8 weeks. This type of intervention is know to modify the metabolic phenotype and expected to change the gut microbiota. Nutritional interventions are planned for 6 months, each subject being studied before (base line), after the intervention (8 weeks) and 2 months after the low calorie diet has stopped and a diet of weight maintenance will be provided. This protocol will be implemented in the nutrition department of the Pitié Salpétrière Hospital in Paris, within the Centre de Recherche en Nutrition Humaine d'Ile-de-France, where patients will be followed on the clinical, biological and histological levels. Evaluation will include medical history, physical, and nutritional evaluations. They will be excluded of the protocol if they had evidence of acute or chronic inflammatory disease, infectious diseases, cancer and/or known alcohol consumption (> 20g per day), as well as other causes of liver, kidney or heart diseases. Physical evaluation will include weight, height, measures of waist/hip ratio, measure of blood pressure. At each time point, body composition will be measured by dual-energy X-ray absorptiometry performed with a total body scanner (Hologic QDR 2500 densitometer). Resting metabolic rate will be evaluated after a one-hour resting period in supine position. Oxygen consumption (VO2) and carbon dioxide production (VCO2), monitored over 30 min by using an open-circuit ventilated-canopy system (Deltatrac II monitor, Datex Instrumentarium Corp., Helsinki, Finland) calibrated with a reference gas. Blood samples will be obtained systematically for biological parameters including lipids (cholesterol, HDL-Chol, TG), insulin and glucose values and OGTT (enabling the determination of insulin sensitivity parameters, adipokines and inflammatory parameters such as leptin, adiponectin, IL-6, TNF alpha, SAA, hsCRP. Serum will be kept for all supplementary measures. The histopathological evaluation of subcutaneous adipose tissue will be performed to evaluate the adipocyte size and the degree of tissue inflammation. Stools samples will be collected for metagenomic studies.
In addition, blood, urine and fecal water samples will be collected and frozen for subsequent metabonomic analysis, and fecal samples for metaproteomic assessment of the microbiota.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01314690
|Assistance publique-hopitaux de Paris|
|Principal Investigator:||Karine Clement, MD, PhD, Prof||Assistance Publique - Hôpitaux de Paris|